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CGGA

:   Chinese Glioma Genome Atlas

GBM

:   glioblastoma

GSEA

:   gene set enrichment analysis

HCC

:   hepatocellular carcinoma

*HOTAIR*

:   *HOX* (homeobox) transcript antisense RNA

HR

:   hazard ratio

IFN

:   interferon

IL

:   interleukin

lncRNA

:   long non‐coding RNA

miRNA

:   microRNA

MMP

:   matrix metalloproteinase

OS

:   overall survival

STAT

:   signal transducer and activator of transcription

TCGA

:   The Cancer Genome Atlas

Glioma is one of the most common types of malignant primary central nervous system tumors with poor prognosis, comprising approximately 44% of central nervous system tumors [1](#feb412601-bib-0001){ref-type="ref"}. The prognosis of glioblastoma (GBM) is the worst among gliomas, in which the median overall survival (OS) for patients with GBM is 15--23 months and the 5‐year survival rate is less than 6% [2](#feb412601-bib-0002){ref-type="ref"}, [3](#feb412601-bib-0003){ref-type="ref"}. Upon diagnosis, the standard treatment of glioma includes maximal surgical resection, chemotherapy, such as temozolomide, and radiation. Treatment options may vary in different stages of the disease and by the age of the patients. Various factors affect the prognosis of GBM including *EGFR* amplifications, and mutations of *IDH1*,*TP53* and *PTEN* [4](#feb412601-bib-0004){ref-type="ref"}, [5](#feb412601-bib-0005){ref-type="ref"}, [6](#feb412601-bib-0006){ref-type="ref"}. However, the survival outcome is unfavorable due to the complex genetic mechanism.

Autophagy is the physiological process that directs degradation of proteins and whole organelles in cells. The activation of autophagy is divided into normal and pathological conditions. Under normal circumstances, autophagy represents a response to several stresses by providing the necessary circulating metabolic substrates for survival. In addition, autophagy is active in some pathological processes in order to maintain cellular homeostasis, such as neurodegenerative diseases, pathogenic inflammation, aging and cancer [7](#feb412601-bib-0007){ref-type="ref"}. In recent years, many studies have sought to find new potential targeted therapies by investigating autophagy pathways [8](#feb412601-bib-0008){ref-type="ref"}, [9](#feb412601-bib-0009){ref-type="ref"}, [10](#feb412601-bib-0010){ref-type="ref"}. In addition, autophagic drugs induce cell autophagic death (type II cell death) and cause glioma cell death. Whether this is an alternative and emerging concept for the study of novel glioma therapies remains largely unknown [11](#feb412601-bib-0011){ref-type="ref"}.

Long non‐coding RNAs (lncRNAs) have a wide range of functional activities [12](#feb412601-bib-0012){ref-type="ref"}. They play a significant role in physiological processes, including RNA decay, genetic regulation of gene expression, RNA splicing, microRNA (miRNA) regulation and protein folding [13](#feb412601-bib-0013){ref-type="ref"}. lncRNA regulates many proteins that are important for autophagy. Impaired functioning of lncRNAs participates in glioma pathogenesis, such as cellular apoptosis and proliferation [14](#feb412601-bib-0014){ref-type="ref"}. *HOX* (homeobox) transcript antisense RNA (*HOTAIR*) is a lncRNA that plays an important role in the regulation of cancer transformation, mainly due to extensive miRNA--*HOTAIR* interactions and its effect on matrix metalloproteinases (MMPs) [15](#feb412601-bib-0015){ref-type="ref"}. There may be an involvement of *HOTAIR*‐interacting miRNAs and MMPs in autophagy regulation [16](#feb412601-bib-0016){ref-type="ref"}, [17](#feb412601-bib-0017){ref-type="ref"}, [18](#feb412601-bib-0018){ref-type="ref"}. Sufficient evidence shows that lncRNAs mediate transcriptional and post‐transcriptional levels of autophagy‐related genes to regulate the autophagy regulatory network [19](#feb412601-bib-0019){ref-type="ref"}, [20](#feb412601-bib-0020){ref-type="ref"}. This paper proposes to construct a coexpression network of autophagy‐related lncRNAs using bioinformatics methods, providing a theoretical basis for the treatment of gliomas [21](#feb412601-bib-0021){ref-type="ref"}.

Therefore, autophagy‐related lncRNAs may have potential value in the prognosis of glioma patients and may serve as potential therapeutic targets. Here, we aimed to establish an autophagy‐related lncRNA signature in glioma and to advance the targeted treatment of glioma.

Materials and methods {#feb412601-sec-0002}
=====================

Information extraction of glioma patients {#feb412601-sec-0003}
-----------------------------------------

The Chinese Glioma Genome Atlas (CGGA, <http://www.cgga.org.cn/>, freely available) microarray was used as a training set to establish an autophagy‐associated lncRNA signature of glioma patients. CGGA is the largest glioma tissue database with follow‐ups in China. Thousands of samples have been subjected to whole‐exome sequencing, DNA methylation microarray detection and whole‐genome sequencing, miRNA, mRNA and circRNA sequencing. The training dataset includes CGGA mRNA expression (FPKM) in 325 glioma patients together with relevant clinical data. The patients were diagnosed based on the 2007 WHO classification guidelines. We downloaded clinical information from the dataset website. The prognostic signature was further validated based on The Cancer Genome Atlas (TCGA, <https://cancergenome.nih.gov/>) GBM dataset. TCGA GBM dataset (FPKM level 3) was included in our analysis as a validation dataset with 160 GBM patients.

LncRNA and autophagy gene screening {#feb412601-sec-0004}
-----------------------------------

The profiles of lncRNAs and autophagy genes were obtained from the CGGA ALL mRNAseq dataset. Specifically, the autophagy gene list was obtained from the Human Autophagy Database (HADb, <http://autophagy.lu/clustering/index.html>). All of the mRNA expression data were normalized by log2 transformation. Pearson correlation was applied to calculate the correlation between the lncRNAs and autophagy‐related genes. A lncRNA with a correlation coefficient \|*R* ^2^\| \> 0.3 and *P* \< 0.05 was considered to be an autophagy‐related lncRNA.

Signature development {#feb412601-sec-0005}
---------------------

First, univariate and multivariate Cox regression analyses were performed to evaluate the prognostic value of autophagy‐related lncRNAs. The lncRNAs with a *P*‐value \< 0.01 by univariate analysis were included in the multivariate stepwise regression Cox analysis to establish the risk score. We used the previous report to determine the risk score for each patient using the following formula: Risk score = β~gene1~ × expr~gene1~ + β~gene2~ × expr~gene2~ + ··· +  β~gene*n*~ × expr~gene*n*~. Cox analysis was performed to build a signature for predicting survival. For more detail, we assigned risk scores by a linear combination of the expression levels of lncRNAs weighted by regression coefficients (β). The β value was calculated by log transformation of the hazard ratio (HR) from the multivariate Cox regression analysis. High‐risk and low‐risk groups were established based on the median risk score. The lncRNA expression is defined as expr~gene*n*~.

Gene set enrichment analysis {#feb412601-sec-0006}
----------------------------

Gene set enrichment analysis (GSEA) was used to interpret gene expression data. This method derives its function by analyzing gene sets, so it can be used to determine whether the gene set shows a statistically significant difference between the two biological states. In this study, we verified whether genes that are differentially expressed between two groups are enriched during autophagy.

Statistical analysis {#feb412601-sec-0007}
--------------------

The expression levels of autophagy‐related lncRNAs were elevated (*P* ≤ 0.05). Construction of the autophagy--lncRNA coexpression network was completed using [cytoscape]{.smallcaps} software [22](#feb412601-bib-0022){ref-type="ref"} (version 3.4.0; The Cytoscape Consortium, San Diego, CA, USA). Pearson correlation analysis and Cox regression analysis were performed using [spss statistics]{.smallcaps} software (version 24; IBM Corp., Armonk, NY, USA). Survival status was the basis for univariate cox regression analysis. [prism]{.smallcaps} 7 (GraphPad Software Inc., La Jolla, CA, USA) was used to generate Kaplan--Meier curves. GSEA ( <http://www.broadinstitute.org/gsea/index.jsp>) was used to distinguish between two sets of functional annotations. Statistical significance was set at a threshold of a two‐tailed *P* \< 0.05.

Results {#feb412601-sec-0008}
=======

Construction of a coexpression network for autophagy--lncRNAs {#feb412601-sec-0009}
-------------------------------------------------------------

We identified a total of 878 lncRNAs in the CGGA dataset, which was extracted from the CGGA database. A total of 215 autophagy‐related genes were extracted from the Human Autophagy Database (HADb, <http://autophagy.lu/clustering/index.html>). We constructed an autophagy--lncRNA coexpression network to identify autophagy‐related lncRNAs. Finally, 402 lncRNAs were identified (\|*R* ^2^\| \> 0.3 and *P* ≤ 0.05).

Identification of a signature of 10 autophagy‐related lncRNAs in patients with glioma {#feb412601-sec-0010}
-------------------------------------------------------------------------------------

First, we identified autophagy‐related lncRNAs by constructing autophagy--lncRNA coexpression networks (*P* ≤ 0.05). In addition, we used univariate Cox regression analysis based on 402 autophagy‐associated lncRNAs to screen prognostic genes. We ranked the prognostic autophagy‐related lncRNAs in ascending order by their *P* values. We used a *P* value of 0.05 as the cutoff value, and the lncRNAs that satisfied this were used for signature development. Our training set was a collection of 325 glioma patients from the CGGA dataset. A total of 19 lncRNAs have prognostic value for glioma patients (*P* \< 0.01). Subsequently, 10 autophagy‐related lncRNAs were found to be independent prognostic factors for glioma patients (Table [1](#feb412601-tbl-0001){ref-type="table"} and Fig. [1](#feb412601-fig-0001){ref-type="fig"}), of which five lncRNAs were unfavorable factors (*TP53TG1*,*ZNF674‐AS1*,*COX10‐AS1*,*DDX11‐AS1* and *SBF2‐AS1*) and five lncRNAs were confirmed to be favorable prognostic factors for glioma (*PCBP1‐AS1*,*DHRS4‐AS1*,*GABPB1‐AS1*,*MAPKAPK5‐AS1* and *MIR4453HG*) (Table [2](#feb412601-tbl-0002){ref-type="table"} and Fig. [2](#feb412601-fig-0002){ref-type="fig"}).

###### 

Correlation between the prognostic lncRNAs and autophagy genes in glioma

  LncRNA           Autophagy gene        Correlation    *P*
  ---------------- --------------------- -------------- ------------
  *PCBP1‐AS1*      *CCL2*                −0.360049202   2.2072E‐11
  *PCBP1‐AS1*      *ATG2B*               0.304817007    2.0467E‐08
  *PCBP1‐AS1*      *KIF5B*               0.305876376    1.818E‐08
  *PCBP1‐AS1*      *ATG2A*               0.311692494    9.4056E‐09
  *PCBP1‐AS1*      *WDFY3*               0.31817447     4.4365E‐09
  *PCBP1‐AS1*      *MLST8*               0.322140176    2.7765E‐09
  *PCBP1‐AS1*      *PIK3C3*              0.324642153    2.0586E‐09
  *PCBP1‐AS1*      *TSC1*                0.330291284    3.8213E‐09
  *PCBP1‐AS1*      *TSC2*                0.332514623    8.3751E‐10
  *PCBP1‐AS1*      *NCKAP1*              0.339888292    3.3348E‐10
  *PCBP1‐AS1*      *GRID2*               0.364527555    5.5069E‐11
  *PCBP1‐AS1*      *SIRT2*               0.366890173    8.5922E‐12
  *PCBP1‐AS1*      *MTOR*                0.371080649    4.7675E‐12
  *PCBP1‐AS1*      *SIRT1*               0.385311738    6.0485E‐13
  *PCBP1‐AS1*      *NBR1*                0.3900753      3.5039E‐13
  *PCBP1‐AS1*      *ERBB2*               0.398520286    8.1268E‐14
  *PCBP1‐AS1*      *BIRC6*               0.401737956    4.9072E‐14
  *PCBP1‐AS1*      *HDAC6*               0.410137987    1.2879E‐14
  *PCBP1‐AS1*      *KIAA0226*            0.417146773    3.9968E‐15
  *PCBP1‐AS1*      *RPTOR*               0.426641207    8.8818E‐16
  *TP53TG1*        *GABARAP*             0.44046552     0
  *TP53TG1*        *TM9SF1*              0.440120961    0
  *TP53TG1*        *VAMP3*               0.43087095     4.4409E‐16
  *TP53TG1*        *ITGB4*               0.379361437    1.4515E‐12
  *TP53TG1*        *LAMP1*               0.362507507    1.5766E‐11
  *TP53TG1*        *RHEB*                0.338549143    3.7103E‐10
  *TP53TG1*        *FADD*                0.322540605    2.6472E‐09
  *TP53TG1*        *RAB7A*               0.320497198    3.3743E‐09
  *TP53TG1*        *HDAC1*               0.316709215    5.2662E‐09
  *TP53TG1*        *ATG4B*               0.310888419    1.0312E‐08
  *TP53TG1*        *DIRAS3*              0.305503826    1.8954E‐08
  *TP53TG1*        *RGS19*               0.300279741    3.5506E‐08
  *DHRS4‐AS1*      *PRKAR1A*             0.304280356    2.6545E‐08
  *DHRS4‐AS1*      *BIRC6*               0.307830991    1.7911E‐08
  *DHRS4‐AS1*      *RPTOR*               0.313316207    9.6535E‐09
  *DHRS4‐AS1*      *WDFY3*               0.314945434    8.0148E‐09
  *DHRS4‐AS1*      *GOPC*                0.319627801    5.2128E‐09
  *DHRS4‐AS1*      *MAPK1*               0.320002607    4.4667E‐09
  *DHRS4‐AS1*      *ST13*                0.322382713    3.3795E‐09
  *DHRS4‐AS1*      *PIK3R4*              0.323543353    2.9471E‐09
  *DHRS4‐AS1*      *NCKAP1*              0.367547056    1.0542E‐11
  *DHRS4‐AS1*      *SIRT1*               0.40099047     7.8826E‐14
  *DHRS4‐AS1*      *NBR1*                0.430691637    6.6613E‐16
  *ZNF674‐AS1*     *ITPR1*               −0.319258764   1.3176E‐08
  *ZNF674‐AS1*     *TP53INP2*            −0.313961307   7.2452E‐09
  *ZNF674‐AS1*     *EIF2S1*              0.304321171    2.163E‐08
  *ZNF674‐AS1*     *PARP1*               0.311082339    1.0086E‐08
  *ZNF674‐AS1*     *HDAC1*               0.311370172    9.7591E‐09
  *ZNF674‐AS1*     *EEF2K*               0.319838206    3.6476E‐09
  *ZNF674‐AS1*     *TM9SF1*              0.321374147    3.0412E‐09
  *ZNF674‐AS1*     *GNAI3*               0.331509862    8.9278E‐10
  *ZNF674‐AS1*     *FKBP1A*              0.339350907    3.3524E‐10
  *ZNF674‐AS1*     *ATG4B*               0.34228221     2.308E‐10
  *ZNF674‐AS1*     *PELP1*               0.342564645    2.226E‐10
  *ZNF674‐AS1*     *FADD*                0.344531987    1.7285E‐10
  *ZNF674‐AS1*     *ENSG00000177993.3*   0.344786314    1.6727E‐10
  *ZNF674‐AS1*     *HGS*                 0.349662833    8.8614E‐11
  *ZNF674‐AS1*     *WDR45*               0.350583974    7.8496E‐11
  *ZNF674‐AS1*     *CAPN10*              0.357666059    3.0499E‐11
  *ZNF674‐AS1*     *RHEB*                0.357722928    3.0266E‐11
  *ZNF674‐AS1*     *MAP1LC3C*            0.358011106    2.9109E‐11
  *ZNF674‐AS1*     *BIRC5*               0.365800568    3.2339E‐11
  *ZNF674‐AS1*     *MAP2K7*              0.37311006     3.5731E‐12
  *ZNF674‐AS1*     *STK11*               0.375183168    2.6561E‐12
  *ZNF674‐AS1*     *GNB2L1*              0.402865027    4.1078E‐14
  *ZNF674‐AS1*     *PRKAB1*              0.411848633    9.77E‐15
  *ZNF674‐AS1*     *EIF4EBP1*            0.441387008    0
  *ZNF674‐AS1*     *RAF1*                0.471527103    0
  *ZNF674‐AS1*     *HDAC6*               0.529212582    0
  *MAPKAPK5‐AS1*   *DLC1*                −0.37599408    2.7613E‐12
  *MAPKAPK5‐AS1*   *CTSB*                −0.321021809   3.1711E‐09
  *MAPKAPK5‐AS1*   *RGS19*               −0.304801176   2.1559E‐08
  *MAPKAPK5‐AS1*   *PRKCD*               −0.303327412   7.978E‐08
  *MAPKAPK5‐AS1*   *APOL1*               −0.301552957   5.851E‐08
  *MAPKAPK5‐AS1*   *EIF2S1*              0.306873043    1.6255E‐08
  *MAPKAPK5‐AS1*   *STK11*               0.316360528    5.4847E‐09
  *MAPKAPK5‐AS1*   *ATG3*                0.317029326    5.073E‐09
  *MAPKAPK5‐AS1*   *GNB2L1*              0.325707112    1.8109E‐09
  *MAPKAPK5‐AS1*   *PRKAB1*              0.332894214    7.5251E‐10
  *MAPKAPK5‐AS1*   *MAP2K7*              0.334240467    6.3674E‐10
  *MAPKAPK5‐AS1*   *ATG4B*               0.342782716    2.1647E‐10
  *MAPKAPK5‐AS1*   *GABARAPL2*           0.344580777    1.7176E‐10
  *MAPKAPK5‐AS1*   *RAF1*                0.368047755    7.3084E‐12
  *MAPKAPK5‐AS1*   *HDAC6*               0.370823221    4.9445E‐12
  *MAPKAPK5‐AS1*   *HGS*                 0.373857161    3.2117E‐12
  *MAPKAPK5‐AS1*   *BID*                 0.396105786    1.1813E‐13
  *MAPKAPK5‐AS1*   *RAB24*               0.404333356    3.2641E‐14
  *MAPKAPK5‐AS1*   *GABARAP*             0.420904922    2.2204E‐15
  *MAPKAPK5‐AS1*   *PELP1*               0.451556383    0
  *MAPKAPK5‐AS1*   *CDKN1B*              0.456366201    0
  *COX10‐AS1*      *MAP1LC3A*            −0.375521773   2.53E‐12
  *COX10‐AS1*      *TP53INP2*            −0.369627107   5.854E‐12
  *COX10‐AS1*      *PINK1*               −0.367447805   7.9483E‐12
  *COX10‐AS1*      *GABARAPL1*           −0.345745019   1.4775E‐10
  *COX10‐AS1*      *HDAC1*               0.30053166     3.2895E‐08
  *COX10‐AS1*      *FKBP1A*              0.305650956    1.8644E‐08
  *COX10‐AS1*      *RB1*                 0.307329731    1.544E‐08
  *COX10‐AS1*      *ATF6*                0.308265668    1.3892E‐08
  *COX10‐AS1*      *HGS*                 0.312518629    8.5551E‐09
  *COX10‐AS1*      *NAF1*                0.313398471    7.7313E‐09
  *COX10‐AS1*      *PIK3C3*              0.323065939    2.4864E‐09
  *COX10‐AS1*      *ITGB1*               0.330112011    1.0601E‐09
  *COX10‐AS1*      *PRKAB1*              0.333014795    7.4136E‐10
  *COX10‐AS1*      *GNB2L1*              0.344926977    1.6425E‐10
  *COX10‐AS1*      *PARP1*               0.345318807    1.5614E‐10
  *COX10‐AS1*      *EIF2S1*              0.3460972      1.4116E‐10
  *COX10‐AS1*      *FADD*                0.361593998    1.7871E‐11
  *COX10‐AS1*      *MYC*                 0.375188431    2.6541E‐12
  *COX10‐AS1*      *EEF2K*               0.377661311    1.8581E‐12
  *COX10‐AS1*      *EIF4EBP1*            0.405855635    2.5757E‐14
  *COX10‐AS1*      *EIF2AK3*             0.419195952    2.8866E‐15
  *COX10‐AS1*      *HDAC6*               0.428787718    4.4409E‐16
  *COX10‐AS1*      *GNAI3*               0.439816001    0
  *COX10‐AS1*      *BIRC5*               0.448936102    0
  *COX10‐AS1*      *RAF1*                0.572860513    0
  *GABPB1‐AS1*     *BID*                 0.420118584    2.4425E‐15
  *GABPB1‐AS1*     *BIRC6*               0.36038314     2.1089E‐11
  *GABPB1‐AS1*     *CASP4*               −0.343935388   5.2362E‐10
  *GABPB1‐AS1*     *CCL2*                −0.373849011   3.2156E‐12
  *GABPB1‐AS1*     *CCR2*                −0.368177579   3.6858E‐11
  *GABPB1‐AS1*     *CDKN1B*              0.364553409    1.1889E‐11
  *GABPB1‐AS1*     *CTSB*                −0.372819935   3.7241E‐12
  *GABPB1‐AS1*     *CTSD*                −0.43970168    0
  *GABPB1‐AS1*     *DAPK1*               0.323366578    2.3986E‐09
  *GABPB1‐AS1*     *DIRAS3*              −0.300618621   3.2582E‐08
  *GABPB1‐AS1*     *DLC1*                −0.313694777   8.3115E‐09
  *GABPB1‐AS1*     *DNAJB1*              −0.308644775   1.3309E‐08
  *GABPB1‐AS1*     *EEF2*                0.36428838     1.2333E‐11
  *GABPB1‐AS1*     *GNB2L1*              0.304868539    2.0349E‐08
  *GABPB1‐AS1*     *GRID2*               0.358164661    1.2447E‐10
  *GABPB1‐AS1*     *HDAC6*               0.583737387    0
  *GABPB1‐AS1*     *KLHL24*              0.37211066     4.1194E‐12
  *GABPB1‐AS1*     *MAP1LC3A*            −0.335686931   5.3165E‐10
  *GABPB1‐AS1*     *MAP2K7*              0.351129758    7.3042E‐11
  *GABPB1‐AS1*     *MYC*                 0.350474546    7.9636E‐11
  *GABPB1‐AS1*     *NAMPT*               −0.317006934   5.0863E‐09
  *GABPB1‐AS1*     *PARP1*               0.318853967    4.0962E‐09
  *GABPB1‐AS1*     *PEA15*               0.306793364    1.6401E‐08
  *GABPB1‐AS1*     *PELP1*               0.350174812    8.2843E‐11
  *GABPB1‐AS1*     *PPP1R15A*            −0.432497553   4.4409E‐16
  *GABPB1‐AS1*     *PRKCD*               −0.354522637   2.4201E‐10
  *GABPB1‐AS1*     *RAF1*                0.518711717    0
  *GABPB1‐AS1*     *SERPINA1*            −0.35246404    9.1958E‐11
  *GABPB1‐AS1*     *SIRT1*               0.377399334    1.9298E‐12
  *GABPB1‐AS1*     *SQSTM1*              −0.300514253   3.2958E‐08
  *GABPB1‐AS1*     *VAMP3*               −0.349193236   9.4249E‐11
  *GABPB1‐AS1*     *WIPI1*               −0.425794454   8.8818E‐16
  *DDX11‐AS1*      *PINK1*               −0.380737586   1.1873E‐12
  *DDX11‐AS1*      *PRKCD*               −0.337496704   1.8761E‐09
  *DDX11‐AS1*      *MAP1LC3A*            −0.321966423   2.8346E‐09
  *DDX11‐AS1*      *TP53INP2*            −0.315547251   6.0291E‐09
  *DDX11‐AS1*      *EIF2AK3*             0.301487968    2.9609E‐08
  *DDX11‐AS1*      *EIF2S1*              0.34484361     1.6603E‐10
  *DDX11‐AS1*      *FKBP1A*              0.36028176     2.1383E‐11
  *DDX11‐AS1*      *MAP2K7*              0.361662635    1.7704E‐11
  *DDX11‐AS1*      *MYC*                 0.36701736     8.4412E‐12
  *DDX11‐AS1*      *PRKAB1*              0.367277985    8.1393E‐12
  *DDX11‐AS1*      *HGS*                 0.398721365    7.8604E‐14
  *DDX11‐AS1*      *PARP1*               0.399014394    7.5051E‐14
  *DDX11‐AS1*      *GNB2L1*              0.446121011    0
  *DDX11‐AS1*      *HDAC6*               0.4630659      0
  *DDX11‐AS1*      *BIRC5*               0.494242839    0
  *DDX11‐AS1*      *EIF4EBP1*            0.494327951    0
  *DDX11‐AS1*      *RAF1*                0.595959165    0
  *SBF2‐AS1*       *SIRT1*               −0.359724478   2.6578E‐11
  *SBF2‐AS1*       *BID*                 −0.359318057   2.8079E‐11
  *SBF2‐AS1*       *EEF2*                −0.345315983   1.7787E‐10
  *SBF2‐AS1*       *HDAC6*               −0.30180643    3.1545E‐08
  *SBF2‐AS1*       *HSPA5*               0.303106799    2.7341E‐08
  *SBF2‐AS1*       *NAMPT*               0.305876474    2.0115E‐08
  *SBF2‐AS1*       *DLC1*                0.313900704    9.0314E‐09
  *SBF2‐AS1*       *PPP1R15A*            0.315700878    6.5975E‐09
  *SBF2‐AS1*       *FKBP1B*              0.330524677    1.1347E‐09
  *SBF2‐AS1*       *WIPI1*               0.347602864    1.3239E‐10
  *SBF2‐AS1*       *DIRAS3*              0.34895202     1.111E‐10
  *SBF2‐AS1*       *CFLAR*               0.353930283    5.7749E‐11
  *SBF2‐AS1*       *CCR2*                0.365426608    6.1051E‐11
  *SBF2‐AS1*       *CASP4*               0.387535164    1.7764E‐12
  *SBF2‐AS1*       *CTSD*                0.39811287     1.0303E‐13
  *SBF2‐AS1*       *RAB33B*              0.41262521     1.0436E‐14
  *SBF2‐AS1*       *MAP1LC3A*            0.466078431    0
  *MIR4453HG*      *BIRC6*               0.482298774    0
  *MIR4453HG*      *CCL2*                −0.32967133    1.1188E‐09
  *MIR4453HG*      *CCR2*                −0.306263916   5.3174E‐08
  *MIR4453HG*      *CDKN1B*              0.37854434     1.6347E‐12
  *MIR4453HG*      *CTSD*                −0.36405224    1.2743E‐11
  *MIR4453HG*      *EEF2*                0.339277778    3.3836E‐10
  *MIR4453HG*      *EIF2AK3*             0.30731381     1.5468E‐08
  *MIR4453HG*      *EIF2S1*              0.300378118    3.3454E‐08
  *MIR4453HG*      *ERBB2*               0.31509245     6.356E‐09
  *MIR4453HG*      *GRID2*               0.33900455     1.3033E‐09
  *MIR4453HG*      *HDAC6*               0.530273615    0
  *MIR4453HG*      *MBTPS2*              0.372080137    4.1376E‐12
  *MIR4453HG*      *MLST8*               0.336179553    4.9987E‐10
  *MIR4453HG*      *NAF1*                0.343120261    2.0729E‐10
  *MIR4453HG*      *NBR1*                0.332149604    9.3012E‐10
  *MIR4453HG*      *NCKAP1*              0.315032585    6.7536E‐09
  *MIR4453HG*      *PIK3C3*              0.398066735    8.7041E‐14
  *MIR4453HG*      *PIK3R4*              0.383400705    8.0247E‐13
  *MIR4453HG*      *RAF1*                0.446543819    0
  *MIR4453HG*      *SERPINA1*            −0.316157599   7.7713E‐09
  *MIR4453HG*      *SIRT1*               0.394985589    1.4033E‐13
  *MIR4453HG*      *ST13*                0.343209924    2.0492E‐10
  *MIR4453HG*      *TSC2*                0.324952539    2.1001E‐09
  *MIR4453HG*      *USP10*               0.330643906    1.3364E‐09
  *MIR4453HG*      *VAMP3*               −0.34420749    1.8024E‐10
  *MIR4453HG*      *WDFY3*               0.321627435    2.9511E‐09
  *MIR4453HG*      *WIPI1*               −0.324415393   2.1154E‐09
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![Network of prognostic lncRNAs with co‐expressed autophagy genes in glioma. In the centric position, grey blue nodes indicate lncRNAs and the sky blue indicates autophagy genes. The coexpression network is visualized by [cytoscape]{.smallcaps} 3.4 software.](FEB4-9-653-g001){#feb412601-fig-0001}

###### 

Detailed information for 10 autophagy‐related lncRNAs significantly associated with OS in glioma

  LncRNA            Ensemble ID       β        SE      *P*        HR      Lower   Upper
  ----------------- ----------------- -------- ------- ---------- ------- ------- -------
  *PCBP1‐AS1*       ENSG00000179818   −0.363   0.184   0.049      0.696   0.485   0.998
  *TP53TG1*         ENSG00000182165   0.443    0.16    0.006      1.558   1.139   2.131
  *DHRS4‐AS1*       ENSG00000215256   −0.253   0.099   0.01       0.776   0.639   0.942
  *ZNF674‐AS1*      ENSG00000230844   0.448    0.199   0.024      1.565   1.06    2.31
  *MAPKAPK5‐AS1 *   ENSG00000234608   −0.64    0.245   0.009      0.527   0.326   0.852
  *COX10‐AS1*       ENSG00000236088   0.829    0.194   \< 0.001   2.29    1.565   3.351
  *GABPB1‐AS1*      ENSG00000244879   −0.403   0.154   0.009      0.668   0.494   0.904
  *DDX11‐AS1 *      ENSG00000245614   0.296    0.128   0.021      1.344   1.046   1.726
  *SBF2‐AS1 *       ENSG00000246273   0.134    0.064   0.036      1.143   1.009   1.295
  *MIR4453HG*       ENSG00000268471   −0.551   0.155   \< 0.001   0.577   0.426   0.781
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![Kaplan--Meier survival curves for the 10 prognostic lncRNAs for glioma in CCGA dataset. The 10 autophagy‐related lncRNAs were found to be independent prognostic factors for glioma patients, of which five lncRNAs were unfavorable factors (*TP53TG1*,*ZNF674‐AS1*,*COX10‐AS1*,*DDX11‐AS1* and *SBF2‐AS1*) and five lncRNAs were confirmed to be favorable prognostic factors for glioma (*PCBP1‐AS1*,*DHRS4‐AS1*,*GABPB1‐AS1*,*MAPKAPK5‐AS1* and *MIR4453HG*).](FEB4-9-653-g002){#feb412601-fig-0002}

The prognostic impact of an autophagy‐related lncRNA signature for glioma {#feb412601-sec-0011}
-------------------------------------------------------------------------

Next, we use a risk score method to develop an autophagy‐related lncRNA signature. We divided the glioma patients into two groups (low‐risk group and high‐risk group) by median risk score (Fig. [3](#feb412601-fig-0003){ref-type="fig"}). As a result, the risk score could significantly predict the OS of glioma patients, in which the OS period is longer in the low‐risk group than that in the high‐risk group (median OS 1211 *vs* 346 days; log rank *P* \< 0.05). Additionally, the Cox regression analysis also revealed a significant prognostic effect of the risk score on the glioma patients (HR = 5.307, 95% CI: 4.195--8.305; *P* \< 0.0001, Fig. [4](#feb412601-fig-0004){ref-type="fig"}). Further, we also explored whether the risk score signature is an independent predictor for the prognosis of glioma patients by multivariate Cox regression analysis. As a consequence, a HR of 2.736 indicated that the risk score could significantly contribute to the prediction of survival of glioma patients, eliminating the influence of other factors such as sex, age, grade, radiotherapy, chemotherapy and the molecular status (*IDHDampR*,*TP53.1*,*EGFR*,*ATRX* and *EZH2*) (Table [3](#feb412601-tbl-0003){ref-type="table"}).

![Autophagy‐related lncRNA risk score analysis of glioma patients in CCGA. (A) The low and high score group for the autophagy‐related lncRNA signature in glioma patients. (B) The survival status and duration of glioma cases. (C) Heatmap of the 10 key lncRNAs expression in glioma. The color from blue to red shows an increasing trend from low levels to high levels.](FEB4-9-653-g003){#feb412601-fig-0003}

![Kaplan--Meier survival curves for the autophagy‐related lncRNA risk score for glioma in CCGA dataset. The Kaplan--Meier survival curves showed that the OS period is longer in the low‐risk group than that in the high‐risk group in the CCGA datasets (median OS 1211 *vs* 346 days; log rank *P* \< 0.05).](FEB4-9-653-g004){#feb412601-fig-0004}

###### 

Multivariate Cox regression analysis of characteristics and risk score in glioma

  Variable       β        SE      Wald     *P*        HR      Lower   Upper
  -------------- -------- ------- -------- ---------- ------- ------- -------
  Gender         −0.022   0.221   0.01     0.921      0.978   0.635   1.507
  Age            0        0.01    0        0.987      1       0.98    1.021
  Grade          0.831    0.16    26.965   \< 0.001   2.296   1.678   3.143
  Radiotherapy   −0.932   0.206   20.553   \< 0.001   0.394   0.263   0.589
  Chemotherapy   −0.469   0.207   5.143    0.023      0.626   0.417   0.938
  *IDHDampR*     −0.639   0.248   6.641    0.01       0.528   0.324   0.858
  *TP53.1*       −0.334   0.186   3.23     0.072      0.716   0.498   1.031
  *EGFR*         −0.165   0.212   0.605    0.437      0.848   0.559   1.285
  *ATRX*         −0.817   0.41    3.98     0.046      0.442   0.198   0.986
  *EZH2*         0.477    0.271   3.104    0.078      1.612   0.948   2.742
  Risk score     1.006    0.243   17.156   \< 0.001   2.736   1.699   4.405
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Clinical value of the lncRNA signature for glioma patients {#feb412601-sec-0012}
----------------------------------------------------------

Subsequently, we also determined the clinical value of the 10‐lncRNA signature regarding the grade, radiotherapy and chemotherapy. As shown in the Table [4](#feb412601-tbl-0004){ref-type="table"}, the risk score tends to increase in the higher grades, suggesting that this lncRNA signature might be associated with the progression of glioma. Interestingly, the risk score was lower in patients receiving radiotherapy than that in patients without radiotherapy (*t* = −2.267, *P* = 0.025). In contrast to the results of radiotherapy, a higher risk score was found in patients without chemotherapy, while the patients who had received chemotherapy presented a lower risk score. Moreover, we also assessed differences in risk score based on molecular status. As a result, lower risk scores were found in those with the *IDH* mutation than in those without, indicating a potential association between the lncRNA signature and *IDH* mutation.

###### 

Clinical impact of risk score signature for the CCGA cohort

  Clinicopathological feature   *n*   Risk score                      
  ----------------------------- ----- ------------- -------- -------- ----------
  Grade                                                               
  I--II                         216   1.203847424   0.8808   10.898   \< 0.001
  III--IV                       109   0.245607385   0.6717            
  Radiotherapy                                                        
  Yes                           212   0.777059137   0.9674   −2.267   0.025
  No                            84    1.029456602   0.8189            
  Chemotherapy                                                        
  Yes                           158   1.01284085    0.8665   2.604    0.01
  No                            128   0.727299406   0.9862            
  IDH (DNA and RNA)                                                   
  Mutation                      171   0.497626264   0.8174   −8.69    \< 0.001
  Wildtype                      154   1.30979323    0.8671            
  IDH1‐R32                                                            
  Wildtype                      162   0.509472199   0.8242   −7.824   \< 0.001
  Mutation                      163   1.253176395   0.8881            
  *TP53.1*                                                            
  Wildtype                      189   0.937494898   0.9505   1.254    0.211
  Mutation                      136   0.805997888   0.9062            
  *EGFR*                                                              
  Wildtype                      110   0.770831973   0.9802   −1.546   0.123
  Mutation                      215   0.939584798   0.905             
  *ATRX*                                                              
  Wildtype                      33    0.856142312   0.9358   −0.171   0.865
  Mutation                      292   0.885443672   0.9343            
  *EZH2*                                                              
  Wildtype                      37    1.182088779   1.1162   1.77     0.084
  Mutation                      288   0.843975569   0.9019            
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Validation in the TCGA dataset {#feb412601-sec-0013}
------------------------------

Next, these results were further validated in the additional dataset (TCGA) using the same β value. In total, 160 GBM patients were enrolled for the validation of the lncRNA signature (Fig. [5](#feb412601-fig-0005){ref-type="fig"}). We divided these patients into the high‐risk and low‐risk groups on the basis of the median value of the risk score. Consistent with the results derived from the CGGA dataset, the high‐risk patients had a shorter median OS than that of the low‐risk patients (median OS 385 *vs* 468 days; log rank *P* = 0.012; Fig. [6](#feb412601-fig-0006){ref-type="fig"}). This finding was further validated by Cox regression analysis, in which the high‐risk group tended to have a shorter OS time for GBM patients than that of the low‐risk group (HR = 1.544, 95% CI: 1.110--2.231; *P* = 0.031). In light of these results, we could confirm that the lncRNA signature provides a robust prediction for the prognosis of glioma patients.

![Autophagy‐related lncRNA risk score analysis of glioma patients in TCGA. (A) The low and high score group for the autophagy‐related lncRNA signature in glioma patients. (B) The survival status and duration of glioma cases. (C) Heatmap of the 10 key lncRNAs expressed in glioma. The color from blue to red shows an increasing trend from low levels to high levels.](FEB4-9-653-g005){#feb412601-fig-0005}

![Kaplan--Meier survival curves for the autophagy‐related lncRNA risk score for glioma in TCGA dataset. Consistent with the results derived from the CGGA dataset, the high‐risk patients had a shorter median OS than that of the low‐risk patients in TCGA datasets (median OS 385 *vs* 468 days; log rank *P* = 0.012).](FEB4-9-653-g006){#feb412601-fig-0006}

Gene set enrichment analysis {#feb412601-sec-0014}
----------------------------

Further functional annotation was conducted through GSEA. The results revealed that the differentially expressed genes between the two groups were enriched in the autophagy‐related and tumor‐related pathways. As result, a total of 19 gene sets were significantly enriched at a nominal *P*‐value \< 5% (Table [5](#feb412601-tbl-0005){ref-type="table"}). Among the gene sets, several pathways are well‐established in cancers, including interleukin (IL) 6/Janus kinase/signal transducer and activator of transcription (STAT) 3 signaling, tumor necrosis factor α signaling via nuclear factor‐κB, IL2/STAT5 signaling, the p53 pathway and the KRAS signaling pathway (Fig. [7](#feb412601-fig-0007){ref-type="fig"}). Moreover, the gene sets were also found to be involved in the vital functions of tumorigenesis and progression of cancer. For instance, epithelial mesenchymal transition, angiogenesis and hypoxia were closely related to the invasion and metastasis of cancer (Fig. [8](#feb412601-fig-0008){ref-type="fig"}). Notably, the GSEA revealed that the gene sets were involved in the reactive oxygen species pathway, interferon (IFN)‐γ response, IFN‐α response and inflammatory response, which are strongly associated with autophagy (Fig. [9](#feb412601-fig-0009){ref-type="fig"}). Taken together, the defined autophagy‐related genes contribute to vital cancer and autophagy pathways, which might provide strong evidence for a cancer‐targeted treatment for glioma.

###### 

Gene set enrichment analysis results based on the signature of 10 autophagy lncRNAs

  Name                                         Size   ES         NES        NOM *P*‐value   FDR *q*‐value   FWER *P*‐value   Rank at max   Leading edge
  -------------------------------------------- ------ ---------- ---------- --------------- --------------- ---------------- ------------- --------------------------------------
  Hallmark_Interferon_gamma_response           194    0.663942   2.002969   0.003831        0.03201         0.019            3784          tags = 62%, list = 18%, signal = 74%
  Hallmark_Coagulation                         134    0.546977   1.968419   0               0.024199        0.027            4273          tags = 47%, list = 20%, signal = 58%
  Hallmark_Allograft_rejection                 196    0.606039   1.934347   0.005894        0.02353         0.037            4277          tags = 59%, list = 20%, signal = 73%
  Hallmark_Epithelial_mesenchymal_transition   195    0.61046    1.914759   0.01354         0.02293         0.051            4360          tags = 62%, list = 20%, signal = 77%
  Hallmark_Interferon_alpha_response           95     0.695722   1.901815   0.007937        0.020948        0.057            3003          tags = 61%, list = 14%, signal = 71%
  Hallmark_Il6_jak_stat3_signaling             86     0.627249   1.854703   0.011905        0.02949         0.083            4232          tags = 60%, list = 20%, signal = 75%
  Hallmark_Tnfa_signaling_via_nfkb             197    0.609462   1.79719    0.024           0.041906        0.129            4243          tags = 58%, list = 20%, signal = 72%
  Hallmark_Angiogenesis                        35     0.582243   1.740052   0.005988        0.059463        0.178            4728          tags = 57%, list = 22%, signal = 73%
  Hallmark_Complement                          192    0.472855   1.732826   0.026263        0.056876        0.188            3996          tags = 45%, list = 19%, signal = 55%
  Hallmark_Hypoxia                             197    0.484747   1.725543   0.034068        0.053391        0.195            3666          tags = 45%, list = 17%, signal = 54%
  Hallmark_Glycolysis                          194    0.445341   1.707246   0.014           0.055343        0.223            4979          tags = 49%, list = 23%, signal = 64%
  Hallmark_Il2_stat5_signaling                 196    0.451793   1.706509   0.017341        0.050981        0.223            5329          tags = 54%, list = 25%, signal = 71%
  Hallmark_Reactive_oxigen_species_pathway     46     0.522081   1.675037   0.017964        0.061012        0.263            2719          tags = 39%, list = 13%, signal = 45%
  Hallmark_Inflammatory_response               194    0.527449   1.670621   0.037549        0.057958        0.266            5277          tags = 59%, list = 25%, signal = 77%
  Hallmark_P53_pathway                         195    0.411785   1.645334   0.027559        0.063102        0.302            4075          tags = 38%, list = 19%, signal = 47%
  Hallmark_Kras_signaling_up                   198    0.419712   1.634183   0.028           0.063116        0.318            4808          tags = 51%, list = 22%, signal = 64%
  Hallmark_Apoptosis                           159    0.432405   1.616621   0.023529        0.066577        0.339            5324          tags = 53%, list = 25%, signal = 71%
  Hallmark_Apical_surface                      44     0.402856   1.481723   0.034483        0.132731        0.539            1498          tags = 23%, list = 7%, signal = 24%
  Hallmark_Mtorc1_signaling                    193    0.417297   1.473019   0.094378        0.130749        0.55             4257          tags = 44%, list = 20%, signal = 54%
  Hallmark_Apical_junction                     195    0.35423    1.457525   0.066148        0.133971        0.567            3822          tags = 33%, list = 18%, signal = 40%

ES, enrichment score; FDR, false discovery rate; FWER, familywise‐error rate; NES, normalized enrichment score; NOM *P* Value, nominal *P* Value.
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![Gene set enrichment analysis indicated significant enrichment of hallmark cancer‐related pathways in the high‐risk group based on CCGA dataset. JAK, Janus kinase; NFKB, nuclear factor‐κB; TNFA, tumour necrosis factor α.](FEB4-9-653-g007){#feb412601-fig-0007}

![Gene set enrichment analysis indicated significant enrichment of the progression‐ and metastasis‐related pathway in the high‐risk group based on CCGA dataset.](FEB4-9-653-g008){#feb412601-fig-0008}

![Gene set enrichment analysis indicated significant autophagy‐related enrichment based on CCGA dataset.](FEB4-9-653-g009){#feb412601-fig-0009}

Discussion {#feb412601-sec-0015}
==========

Glioma is the most aggressive and common type of primary brain tumor in humans. With the development of clinical management of glioma, some prognostic factors are well characterized, including tumor size, tumor grade and stage. High‐throughput biological technologies are being widely used to predict cancer recurrence and tumor metastasis by detecting the alteration of miRNAs or genes [23](#feb412601-bib-0023){ref-type="ref"}, [24](#feb412601-bib-0024){ref-type="ref"}. The major class of lncRNAs, as a complement to genes or miRNAs, provides a promising opportunity to predict the risk of recurrence of glioma [25](#feb412601-bib-0025){ref-type="ref"}. However, so far, there has been no systematic process to identify lncRNA signature sets for predicting the survival of glioma patients. Therefore, it is necessary to establish a lncRNA signature to predict the prognosis of glioma patients.

In this study, two datasets (CGGA and TCGA) were collected to explore the prognosis of autophagy‐related lncRNAs for glioma patients. In the first step, we identified 402 lncRNAs through the lncRNA--autophagy gene co‐expression network. Furthermore, we identified 10 autophagy‐associated lncRNA signatures that could divide glioma patients into high‐ and low‐risk groups based on the median risk score. Additionally, it was found that the OS is longer in the low‐risk group than that in the high‐risk group. Through univariate and multivariate Cox regression analyses, we can conclude that the signature is an independent factor that is significantly related to OS.

Although little is known about the role of autophagy in cancer therapy to date, recent studies suggest that autophagy therapy will become a new approach to glioma treatment [26](#feb412601-bib-0026){ref-type="ref"}, [27](#feb412601-bib-0027){ref-type="ref"}. In recent studies, IFN‐γ was found to influence autophagy and cell growth in human hepatocellular carcinoma (HCC) cells. IFN‐γ is a cytokine with anti‐viral and immune regulation. The cytokine induces autophagosome formation and transformation of microtubule‐associated protein 1 light chain 3 proteins and can inhibit cell growth and non‐apoptotic cell death in Huh7 cells. In addition, autophagy in Huh7 cells is also activated by the overexpression of interferon‐regulatory factor‐1. Eventually, induced autophagy will inhibit IFN‐γ and cell death in HCC [28](#feb412601-bib-0028){ref-type="ref"}. Since autophagy can respond to a variety of stresses to promote the survival of cancer cells, it has protumorigenic functions. Glucose metabolism promotes adhesion‐independent conversion driven by oncogene insult‐mutationally active Ras. In human cancer cell lines carrying KRAS mutations and cells ectopically expressing oncogenic H‐Ras, autophagy is induced after the extracellular matrix is isolated. If autophagy is inhibited by RNA interference‐mediated depletion of multiple autophagic regulators or genetic deletion, Ras‐mediated conversion and glycolytic capacity proliferation independent of adhesion will be impaired. In addition, when the availability of glucose is decreased, the conversion and proliferation of autophagy‐deficient cells expressing oncogenic Ras are unaffected, which is just the opposite of that in autophagy‐competent cells. In conclusion, autophagy can promote the unique mechanism of Ras‐driven tumor growth in specific metabolic environments [29](#feb412601-bib-0029){ref-type="ref"}.

Among the 10 autophagy‐related lncRNAs, *PCBP1‐AS1*,*DHRS4‐AS1*,*MAPKAPK5‐AS1* and *GABPB1‐AS1* were risk‐associated genes, while *TP53TG1*,*ZNF674‐AS1*,*DDX11‐AS1*,*SBF2‐AS1*,*MIR4453HG* and *COX10‐AS1* were protective genes. Specifically, we also found that the high‐risk group was enriched in the glycolysis pathway. Consistent with our studies, a recent study revealed that *TP53TG1* might affect the expression of glucose metabolism‐related genes under glucose deprivation, leading to cell proliferation and migration of glioma cells [30](#feb412601-bib-0030){ref-type="ref"}. Additionally, *MAPKAPK5‐AS1* regulates gene expression by acting with miRNAs and is significantly associated with the OS of liver cancer [31](#feb412601-bib-0031){ref-type="ref"}. Furthermore, the expression of *COX10‐AS1* in oral cavity and oropharyngeal squamous cell carcinoma is more than twice that of normal cells [32](#feb412601-bib-0032){ref-type="ref"}.

All of the lncRNAs we identified directly or indirectly regulate autophagy, many by regulating miRNAs; thus, we must perform lncRNA--mRNA co‐expression analyses to assess the function of lncRNAs [33](#feb412601-bib-0033){ref-type="ref"}, [34](#feb412601-bib-0034){ref-type="ref"}, [35](#feb412601-bib-0035){ref-type="ref"}. Therefore, we can conclude that due to the various functions of lncRNAs, the 10 autophagy‐related lncRNAs we identified will be potential therapeutic targets [12](#feb412601-bib-0012){ref-type="ref"}, [36](#feb412601-bib-0036){ref-type="ref"}.

In conclusion, by constructing an autophagy--lncRNA coexpression network, we identified a signature of 10 autophagy‐related lncRNAs, which has prognostic value for glioma patients. In addition, our study classified low‐risk and high‐risk groups based on the median risk score, and each showed different autophagy states.
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